Roger Williams Medical Center, Boston University School of Medicine, Roger Williams Medical Center, Providence, RI, USA.
J Clin Rheumatol. 2013 Mar;19(2):90-3. doi: 10.1097/RHU.0b013e3182863027.
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton. Extra-articular manifestations are less common relative to other rheumatic diseases, and vasculitic complications typically involve the ascending aorta and aortic valve. The use of tumor necrosis factor inhibitors is efficacious in the treatment of patients with AS. Since their routine use, however, tumor necrosis factor inhibitors have been associated with the development of drug-induced complications including the induction of lupus and both cutaneous and systemic vasculitis. In this report, we describe a patient with severe longstanding AS, who developed Henoch-Schönlein purpura after commencing therapy with etanercept. Tumor necrosis factor inhibitor-induced Henoch-Schönlein purpura has been very rarely reported and has been mostly recognized in patients with rheumatoid arthritis.
强直性脊柱炎（AS）是一种慢性炎症性疾病，主要影响中轴骨骼。相对于其他风湿性疾病，关节外表现较少见，血管炎并发症通常累及升主动脉和主动脉瓣。肿瘤坏死因子抑制剂在治疗 AS 患者方面是有效的。然而，自从它们常规使用以来，肿瘤坏死因子抑制剂已与药物诱导的并发症的发展相关，包括诱导狼疮以及皮肤和系统性血管炎。在本报告中，我们描述了一名患有严重慢性强直性脊柱炎的患者，在开始使用依那西普治疗后发生了过敏性紫癜。肿瘤坏死因子抑制剂诱导的过敏性紫癜非常罕见，主要见于类风湿关节炎患者。
